We chat about longevity with Alex Zhavoronkov, CEO and founder of the artificial intelligence (AI) specialist Insilico Medicine.
Born in Latvia, Alex founded Insilico in 2014, with the company raising a huge $110M Series E round this year.
Alex gives us a tour of Insilico’s sprawling pipeline, a blunt rundown of the competitive landscape in AI drug development, and explains how Insilico is navigating the huge challenges faced by longevity-focused startups.
⭐️ ABOUT THE SPEAKER
Alex founded Insilico in 2014 after serving in senior roles at ATI Technologies, NeuroGNeuroinformatics, and the Biogerontology Research Foundation.
With an academic background in biomedicine and computer technology, he has published more than 200 peer-reviewed articles, and has bachelor’s degrees from Queen's University, Canada, a master’s degree from Johns Hopkins University, US, and a PhD from Moscow State University, Russia.
🔗 LINKS MENTIONED
📜 TRANSCRIPTRead the full transcript here:
https://flot.bio/episode/alex-zhavoronkov-insilico-medicine-ai-drug-development-longevity/
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.
⏰ TIMESTAMPS
We jet off to Central London to meet Robin Carr, CEO of Myricx Bio, a startup developing antibody-drug conjugates (ADCs) to treat cancer.
The team’s idea – using a novel ADC payload inhibiting molecules called N-myristoyltransferases (NMTs) – helped them to bag an impressive £90M ($114M) Series A round in 2024.
Robin outlines Myricx’s journey from small molecule antivirals to the booming market of cancer ADCs, and how the transition from big pharma to biotech has been an energising experience for him.
--------------------This episode is sponsored by Kadans. Learn more about Kadans’ London Innovation Centre where life sciences companies grow from start-up to global player: https://bit.ly/kadans-myricxbio--------------------
⭐️ ABOUT THE SPEAKER
Robin kicked off his Myricx experience as chief development officer in November 2019, before rising to the CEO seat in August 2022. Before this, he was VP of drug discovery at Astex Therapeutics, before spending more than a decade in research executive roles at GSK. ending up as SVP Drug Design and Selection.
🔗 LINKS MENTIONED
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/robin-carr-myricx-bio-adc/
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.
⏰ TIMESTAMPS
We dive into the world of cutting-edge cancer treatments with Aino Kalervo, Chief Operating Officer of TILT Biotherapeutics and occasional tennis legend in her spare time.TILT recently closed a $25M series B round, backed by leading Finnish investors, to finance the clinical development of its oncolytic virus candidate to supercharge cancer immunotherapies.We also explore the challenging space of oncolytic viruses and the untapped potential of biotech innovation in Finland.______For transparency, this episode has been sponsored by TILT.______⭐️ ABOUT THE SPEAKERAino Kalervo is the Chief Operating Officer of TILT Biotherapeutics, responsible for fundraising and business development. She has also served as the president of TILT’s US affiliate since 2022. Prior to joining TILT, she worked for Sanofi and the French therapeutic vaccine company Theravectys.🔗 LINKS MENTIONED- TILT Biotherapeutics’ website: https://tiltbio.com/- TILT’s Series B round: https://tiltbio.com/userassets/uploads/2025/05/TILT-Series-B-press-release-May-2025.pdf- Marina Udier, Nouscom 🇨🇭 | Cancer Vaccines, Neoantigens | E21 - Flot.bio: https://flot.bio/episode/marina-udier-nouscom-cancer-vaccines/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/aino-kalervo-tilt-immunotherapy/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:01:44] Inside TILT’s $25M series B round[00:04:04] Multi-action oncolytic viruses[00:10:54] Learning from their peers[00:14:07] Phase 1 for melanoma[00:21:14] Collaborations and competitors[00:23:17] From Helsinki to global trials[00:33:03] Finland’s biotech ecosystem[00:39:00] Aino Kalervo’s personal path[00:45:43] Quickfire
Fresh after leading Calliditas Therapeutics through a $1.1B acquisition, Renee Aguiar-Lucander takes us through her new CEO role at Hansa Biopharma 🇸🇪.We learn how Hansa is commercialising Idefirix, its lead product for improving outcomes in kidney transplantation. We also cover the hot area of immunology, the behind-the-scenes story behind Calliditas’ takeover and the complex world of biotech financing.-----Launching a biotech startup? Grab your Biotech Starter Kit through Merck’s New Lab Starter Program and get the tools and support you need from day one: https://bit.ly/biotech-starter-kit----⭐️ ABOUT THE SPEAKERRenee Aguiar-Lucander became the CEO of Hansa Biopharma in April 2025 after a seven-year tenure as CEO of Calliditas Therapeutics, which Asahi Kasei Corporation acquired in September 2024. Before her CEO roles, she also had a long career in healthcare investments with senior roles in funds including Omega Fund Management and 3i Group.🔗 LINKS MENTIONED- Hansa Biopharma’s Interim Report Q1 April 2025: https://www.hansabiopharma.com/files/Main/1219/4138498/20250423-hnsa--q1-2025-quarterly-report-eng.pdf- The acquisition announcement of Calliditas Therapeutics by Asahi Kasei: https://asahi-kasei.eu/acquire-calliditas-therapeutics-ab/- Hansa Biopharma’s website: https://www.hansabiopharma.com/- Marc de Garidel, Abivax | How to make two Billion-dollar exits ("smoothly") | E09: https://flot.bio/episode/marc-de-garidel-abivax-exit/- Christophe Bourdon, LEO Pharma 🇩🇰 | Biopharma Turnaround | E31: https://flot.bio/episode/christophe-bourdon-leo-pharma-biopharma/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/renee-aguiar-lucander-hansa/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:02:18] Joining Hansa Biopharma- [00:03:23] How Idefirix works- [00:06:45] Commercialization and competition- [00:15:24] Navigating biotech finances- [00:19:51] Lessons from Calliditas’ exit- [00:27:11] Sofinnova and European crossover funds- [00:41:23] Immunology is hot- [00:44:04] Financing to management- [00:47:54] Women leading biotech- [00:50:20] Quickfire
We’re with Stephane Bancel, CEO of the US mRNA giant Moderna. The company’s 15-year trajectory has taken it from the startup seed stage to a commercial heavyweight with three mRNA-based products in the market 🧬
We go in-depth into Stephane’s leadership style and background before delving into Moderna’s research and the evolution of the mRNA space.
⭐️ ABOUT THE SPEAKER
Stéphane Bancel joined mRNA therapeutics company Moderna as CEO in 2011 and led its efforts to develop a commercial COVID-19 vaccine during the global pandemic in 2020. Prior to this, he held senior roles in the pharmaceutical and biotech sectors, including CEO of bioMérieux and Country Manager for Belgium at Eli Lilly.
🔗 LINKS MENTIONED
- Moderna website: https://www.modernatx.com/
- Moderna partners with OpenAI: http://investors.modernatx.com/news/news-details/2024/Moderna-and-OpenAI-Collaborate-To-Advance-mRNA-Medicine/default.aspx
- Ingmar Hoerr, CureVac | Founding a €20B Biotech | E03: https://flot.bio/episode/ingmar-hoerr-curevac-founding-a-20b-biotech-and-almost-dying-as-ceo/
- Harpreet Singh, Immatics 🇩🇪 | PRAME, TCR Based Therapeutics | E20:https://flot.bio/episode/harpreet-singh-immatics/
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/stephane-bancel-moderna-mrna/
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.
⏰ TIMESTAMPS
- [00:00:00] Intro
- [00:01:44] Building an effective team
- [00:04:10] The Boston biotech mafia
- [00:09:10] mRNA as a platform
- [00:09:10] mRNA as a platform
- [00:12:25] The transition to entrepreneurship
- [00:27:31] mRNA pionners
- [00:36:32] Innovation at scale
- [00:47:12] Beyond vaccines
- [00:53:38] AI everywhere
- [00:55:16] Quickfire
We’re online with Chris Martin, COO of the 6th most valuable biotech in Europe, Verona Pharma. Their amazing story sees them bring a fully-owned respiratory drug to market and multiply its valuation by 120x within the last 5 years (from $50M to $6B today) 💸We talk about the commercial rollout of Ohtuvayre, Verona’s drug. We also discuss the British roots of the company and why execution is the most important in biotech.⭐️ ABOUT THE SPEAKERChris Martin joined Verona Pharma as their COO in 2020. He’s at the helm of Verona’s commercial strategy, driving the company’s progress in respiratory medicine. Before Verona, Chris played a key role as Executive Director of Marketing at SK Life Science, where he helped launch the CNS treatment XCOPRI® (cenobamate tablets). He also led the marketing efforts at Cempra, guiding the launch of their first product, and spent a decade at Salix Pharmaceuticals, where he led the Xifaxan® marketing team through its acquisition by Valeant Pharmaceuticals.🔗 LINKS MENTIONED- Verona Pharma’s corporate presentation: https://www.veronapharma.com/wp-content/uploads/2025/04/VRNA-Presentation-May-2025.pdf- Verona website: [http://veronapharma.com](http://veronapharma.com/)- Ohtuvayre website: [http://ohtuvayre.com](http://ohtuvayre.com/)- Q1 2025 results: https://www.veronapharma.com/news/verona-pharma-reports-first-quarter-2025-financial-results-and-provides-corporate-update/- Royalty pharma website: [https://www.royaltypharma.com](https://www.royaltypharma.com/)- Adrian Rawcliffe, Adaptimmune 🇬🇧 | Tecelra, TCR Cell Therapy | E22: https://flot.bio/episode/adrian-rawcliffe-adaptimmune/- Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity, and AI | E14: https://flot.bio/episode/bahija-jallal-immunocore/
- The 25 Most Valuable Biotech Companies in Europe in 2025: https://flot.bio/most-valuable-biotech-companies-europe-2025/
📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/chris-martin-verona-pharma-copd/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:02:04] Commercial rollout of Ohtuvayre- [00:06:42] Fierce competition in COPD- [00:10:34] UK origins of Verona Pharma- [00:21:24] Strong Clinical data for Chronic Disease Patients- [00:26:01] Reaching Profitability for Verona Pharma- [00:30:58] Chris Martin Joining Verona Pharma- [00:34:51] Execution is Key to Success in Biotech- [00:42:48] How to get to the top in Biotech without a background in science- [00:46:33] Royalty model in Biotech- Quickfire
We’re online with Daniela Marino, CEO and co-founder of one of the best companies in Europe for tissue therapeutics, CUTISS.We discussed the story behind CUTISS and its current series C fundraising. We also discussed cell therapy in general and why kids are good at preventing burnout.---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue therapies. Learn how you can support CUTISS on its path to Series C success: https://bit.ly/flotbio-cutiss---⭐️ ABOUT THE SPEAKERIn 2023, Daniela Marino was named as one of the 30 Rising Leaders in the healthcare industry, thanks to the impact of CUTISS, the company she co-founded as a spin-off from the University of Zurich. Here, she and her team have made waves for people suffering from severe skin injuries and defects through regenerative medicine, tissue engineering, and skin pigmentation.🔗 LINKS MENTIONED- CUTISS Homepage (technology, about us): [https://cutiss.swiss](https://cutiss.swiss/)- CUTISS Deck Series C: https://cutiss.swiss/wp-content/uploads/2025/03/CUTISS-AG-Teaser-Q1-2025_Series-C.pdf- Thomas Ybert, DNA Script 🇫🇷 | DNA Printing & Synthesis | E27: https://flot.bio/episode/thomas-ybert-dna-script-dna-printing/- Ingmar Hoerr, CureVac | Founding a €20B Biotech | E03: https://flot.bio/episode/ingmar-hoerr-curevac-founding-a-20b-biotech-and-almost-dying-as-ceo/- Giammaria Giuliani profile https://www.forbes.com/profile/giammaria-giuliani/- Hansjorg Wyss profile - [https://en.wikipedia.org/wiki/Hansjörg_Wyss](https://en.wikipedia.org/wiki/Hansj%C3%B6rg_Wyss)📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/daniela-marino-cutiss-skin-tissue-therapeutics/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:01:41] Story of CUTISS[00:04:47] Positive Phase 2 Data[00:16:03] Raising a Series C[00:26:34] Next steps for CUTISS[00:31:46] Cell Therapy and Tissue Therapy landscape[00:42:36] US Biotech Market[00:45:12] TechBio, Hardware and Automation[00:50:58] Kids preventing burnout[00:54:18] Daniela Marino, Academic and Female Founder[01:01:10] Quickfire
We’re in Barcelona 🇪🇸 with Joris Pezzini from Alira Health to discuss the hottest biotech insights right now, including obesity, I&I, radiopharmaceuticals and ADCs.---This episode is sponsored by Alira Health, an advisor and clinical development partner for life sciences companies. Learn more at https://bit.ly/alirahealth-flotbio-1---⭐️ ABOUT THE SPEAKERJoris Pezzini has been in the biotech world for over 15 years. Before joining Alira Health in 2019, he had worked in some top pharma and biotech companies across the US, UK and France, including UCB, LFB, and Bionest Partners. Through this combo of roles as a Biopharma executive in start-ups, mid-sized, pharma, and consulting firms, Joris has a good eye on the industry with a wealth of experience and knowledge.🔗 LINKS MENTIONED- Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset **-** https://www.fiercebiotech.com/biotech/roche-fattens-obesity-pipeline-paying-zealand-165b-upfront-co-develop-amylin-asset- Medicine 3.0: What It Is and Why You Need It - Hone Health - https://honehealth.com/edge/medicine-3-0-peter-attia/📜 TRANSCRIPTRead the full transcript here: 💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:02:17] Hottest biotech industry trends according to Joris Pezzini- [00:11:14] Medicine 3.0- [00:13:22] ADCs and Radiopharmaceuticals- [00:17:00] The “end” of the blockbuster model- [00:20:35] Challenges to raise money- [00:27:41] Transatlantic & China- [00:33:04] The success story of Alira- [00:44:50] Investing in real-world evidence and AI- [00:48:53] Background in bioprocessing- [00:58:20] Bridging biotech and healthy lifestyle- [01:05:42] Quickfire
We’re in Copenhagen 🇩🇰 with Christophe Bourdon, the CEO who turned a 116-year-old biopharma company from the brink of failure to success.We discuss the lessons behind the turnaround, innovation in dermatology, especially biologicals and I&I, and living in eight different countries.⭐️ ABOUT THE SPEAKERChristophe Bourdon came to be CEO of LEO Pharma in 2022, where he was tasked with the massive assignment of transforming the financially failing company into a success. Luckily he had gained experience in roles of increasing leadership importance in many EU biotech companies, Sanofi, Amgen, and Alexion, as well as leading the smaller biotech, Orphazyme A/S, as their CEO. Now Leo Pharma is in the green.🔗 LINKS MENTIONED- Marc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09: https://flot.bio/episode/marc-de-garidel-abivax-exit/- Jens Nielsen, BII | How to make translation of life science research work | E12: https://flot.bio/episode/jens-nielsen-translation-of-life-science-research/- On the Origin of Species: Charles Darwin: https://tinyurl.com/2nbhkecs- Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma: https://www.fiercebiotech.com/biotech/gilead-roars-jpm25-250m-upfront-research-deal-leo-pharma- Homepage LEO Pharma, history and pipeline: http://leo-pharma.com/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/christophe-bourdon-leo-pharma-biopharma/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:01:54] Turnaround of LEO Pharma[00:08:47] Current products at LEO Pharma[00:17:28] STAT6 Protein Degrader, deal with Gilead[00:23:34] Immunology & Inflammation is hot[00:28:26] Pipeline of LEO Pharma & Dealmaking[00:38:20] Finance & IPO[00:45:03] Living & working in 8 countries[00:48:17] Quickfire
We’re in Munich 🇩🇪 with Cristoph Broja, Partner at EQT Life Sciences, the top venture capital firm in Europe.We talk about his lessons up until becoming a partner at the firm. We also talk about how to invest in hot areas such as obesity or ADCs, and the importance of being curious. ⭐️ ABOUT THE SPEAKERCristoph Broja has been a Partner at EQT Life Sciences since 2022. Prior to this, he found himself in a myriad of biotechs, such as being part of the investment team of the Boston-based Gurnet Point Capital, as well as B-Flexion Capital in London.🔗 LINKS MENTIONED- Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC Biotech ⭐️ | E19: https://flot.bio/episode/dominik-schumacher-tubulis/- Claudia Ulbrich, Cardior 🇩🇪 | Being the Founder of a Rare €1B Exit | E15: https://flot.bio/episode/claudia-ulbrich-cardior/- René Kuijten, Head of EQT Life Sciences, on BioStock: [https://www.linkedin.com/posts/rené-kuijten-b503a1_collaboration-startups-investors-ugcPost-7293582558116663297-9Q-M](https://www.linkedin.com/posts/ren%C3%A9-kuijten-b503a1_collaboration-startups-investors-ugcPost-7293582558116663297-9Q-M?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAXuQREBNiVcFS8XPp62vaHeZfMBR6F5yK0)📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/christoph-broja-eqt-vc/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:01:51] Becoming partner at EQT Life Sciences- [00:02:48] Getting to the top in biotech without a life science degree- [00:10:40] Moving back to Europe- [00:13:19] Investments in ADCs, Tubulis, Cardior- [00:28:28] LSP 7, biggest venture fund in Europe- [00:35:07] Observing the Chinese biotech scene very closely- [00:39:05] Marriage between LSP and EQT- [00:48:41] Focus on M&A vs IPO- [00:59:17] Quickfire
We’re in Munich with Philipp Baaske, one of the best life science tools founder in Europe.
We talked about the lessons building this life science tools business specialized in protein interactions. We also talked about the difficulty and rewards of entrepreneurship, and the impact of life science tools.
___
This episode is sponsored by NanoTemper Technologies, which performs protein characterization. Learn more at https://bit.ly/flotbio_nanotemper
___
⭐️ ABOUT THE SPEAKER
Philipp Baaske, a German biophysicist, co-founded NanoTemper Technologies in 2008 with Stefan Duhr. He earned his PhD from Ludwig-Maximilians-University Munich, specializing in biophysics. Baaske pioneered MicroScale Thermophoresis, advancing drug discovery research. He was Co-CEO for 16 years before becoming Executive Chairman in 2024. An award-winning innovator, he supports biotech and entrepreneurship as a business angel.
🔗 LINKS MENTIONED
📜 TRANSCRIPT
Read the full transcript here: coming soon
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.
⏰ TIMESTAMPS
We’re online 🇸🇪 with Mathias Uhlen, one of the best entrepreneurial scientists in Europe.
We talked about the entrepreneurial mindset in academia. We also talked about AI for biology and why he doesn’t believe in the current anti-ageing drugs.
⭐️ ABOUT THE SPEAKER
Looking at the career of Mathias Uhlen can only leave you feeling impressed. He has co-founded or invested in 26 startups while having published over 800 papers, and creating the Human Protein Atlas, one of the most successful biology projects ever. He was also the Founding Director of Science for Life Laboratory (SciLifeLab), a national project with the Swedish government to help technology and data-driven research in support of European life science research.
🔗 LINKS MENTIONED
- New innovation award celebrates entrepreneurs who have taken on big challenges: https://www.kth.se/en/om/nyheter/centrala-nyheter/nytt-innovationspris-hyllar-entreprenoren-som-tar-sig-an-stora-utmaningar-1.1049278
- Jens Nielsen, BII | How to make translation of life science research work | E12: https://flot.bio/episode/jens-nielsen-translation-of-life-science-research/
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/mathias-uhlen-entrepreneur/
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.
⏰ TIMESTAMPS
- [00:00:00] Intro
- [00:02:05] How Mathias Uhlen co-founded 26 startups
- [00:10:55] Entrepreneurial mindset
- [00:15:10] Entrepreneurial scientist in Europe
- [00:18:43] Developing tools for research in biotech
- [00:20:53] Human Protein Atlas
- [00:24:55] AI for biology and AlphaCell
- [00:34:35] Lessons for younger academics
- [00:37:24] Combination of tech and biology
- [00:40:57] False promises of anti-ageing
- [00:44:48] Quickfire
- [00:48:35] Thanks for listening
We’re online 🇫🇷 with Thomas Ybert, the co-founder of DNA Script, the leading biotech for DNA printing of oligos.
We talked about the commercialization of the first DNA printer. We also talked about company building at large and how to expand to the US successfully.
⭐️ ABOUT THE SPEAKER
At just 30 years old, Thomas Ybert co-founded DNA Script in 2014 in Paris. Previously he worked in R&D at Sanofi before joining Total in the New Energies Division where he contributed to the bio jet-fuel project in collaboration with Amyris. It was here he developed his passion for manufacturing synthetic DNA which moved him from the world of academic research to a startup.
🔗 LINKS MENTIONED
📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/thomas-ybert-dna-script-dna-printing/
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.
⏰ TIMESTAMPS
We’re at BIO-Europe in Stockholm 🇸🇪 with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer's.
We talked about the science and business behind Leqembi. We also talked about the Alzheimer’s field at large and transitioning from big pharma to biotech.
— — —
Thank you to today’s sponsor, Turbine, who is organizing a free Techbio event at JPM25 and is inviting you to join. Click the link to RSVP and secure one of the limited spots:
https://www.turbine.ai/jpm25-event-registration
— — —
⭐️ ABOUT THE SPEAKER
Gunilla joined BioArctic in 2013 after many successful years in executive positions at Astra/AstraZeneca, including Vice President for the product portfolio of neurodegenerative diseases. Since joining BioArctic, the largest Swedish biotech, Leqembi, one of the only successful drugs for Alzheimer’s was approved. This was an invention of BioArctic that Eisai and Biogen have commercialized. This is a particularly impressive feat considering 98% of Alzheimer’s drugs fail.
🔗 LINKS MENTIONED-
The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more: https://www.biotechtv.com/post/bioarctic-gunilla-osswald-september-21-2024
- Roche sees rapid amyloid clearing in Alzheimer's study, adjusts protocol after patient death: https://www.fiercebiotech.com/biotech/roche-sees-rapid-amyloid-clearing-early-alzheimers-study
- Edwin Moses | How to build large biotech platforms | E13: https://flot.bio/episode/edwin-moses-biotech-platforms/
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/gunilla-osswald-bioarctic-alzheimers/
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.
⏰ TIMESTAMPS
[00:00:00] Intro
[00:02:24] Leqembi and BioArctic
[00:10:40] Side effects of Leqembi for Alzheimer's treatment
[00:17:03] Passing the blood-brain barrier for better Alzheimer's treatments
[00:21:00] Market access for Leqembi in Europe
[00:27:03] Gunilla Osswald's commitment to patients
[00:31:55] Leaving AstraZeneca, transitioning to biotech
[00:38:42] Unique culture at BioArctic
[00:42:26] Alzheimer's field in Europe and at large
[00:48:20] Quickfire
[00:53:42] Thanks for listening
We’re in Hamburg with Sean Marett, who has been instrumental to the success of BioNTech for 12 years.
We talked about the secrets behind BioNTech’s success. We also talked about the art of dealmaking and working with China.
⭐️ ABOUT THE SPEAKER
Sean joined BioNTech in 2012 as part of the Management Board. He was instrumental in the growth of the company and global expansion through business development and product commercialization. Prior to BioNTech Sean worked in top companies such as GlaxoSmithKline, Pfizer, Evotec, and Lorantis. I first met Sean in 2015 in Berlin, when BioNTech had no website, but was already the largest private biotech in Europe. Now Sean has retired from BioNTech after 12 years but still aids the company as a specialist consultant.
🔗 LINKS MENTIONED
- BioNTech Announces Planned Retirement of Sean Marett: https://investors.biontech.de/news-releases/news-release-details/biontech-announces-planned-retirement-sean-marett
- BioNTech pays $800M to take control of potential Keytruda killer: https://www.fiercebiotech.com/biotech/biontech-pays-800m-take-control-potential-keytruda-killer
- Sean Marett, COO at BioNTech, on the Future of mRNA Therapies - 2015: https://www.youtube.com/watch?v=6zrDKRvsAEU
📜 TRANSCRIPT
Read the full transcript here:
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.
⏰ TIMESTAMPS
- [00:00:00] Intro
- [00:01:45] Sean Marett stepping down as CBO of BioNTech
- [00:05:10] From Pfizer to BioNTech
- [00:15:28] Building a biotech in Mainz
- [00:29:02] The art of biotech dealmaking
- [00:45:29] Mistakes in dealmaking
- [00:57:45] Biotech dealmaking in China
- [01:04:25] Managing energy
- [01:08:17] Quickfire
- [01:13:57] Thanks for listening
In our first episode recorded live in front of an audience, we’re with Lovisa Afzelius, the General Partner of the European branch of Flagship Pioneering 🇸🇪 We talk about Flagship, including its EU activities. We also talk about company-building and Lovisa’s personal journey to be one of the leading Swedish leaders in biotech. ⭐️ ABOUT THE SPEAKER Lovisa is an icon in the EU biotech and pharma world, having been a CEO, co-founder, president, board chairman, and executive director in many emerging companies. Joining Flagship in 2020, she became the founding CEO of Alltrna, and co-founded/CEO of Apriori Bio, Metaphore Biotechnologies, and Prologue Medicines. Lovisa has received many accolades. A few include being listed on Inc. Magazine’s Female Founders 250 List in 2024, 2023 she featured in the PharmaVoice 100 list of life science industry leaders. 🔗 LINKS MENTIONED - tRNA therapies, Lovisa Afzelius, Founding CEO, Theonie Anastassiadis, Co-founder & CIO, Alltrna: https://open.spotify.com/episode/3JaGad1YednEhExnK4Xl2L?si=7G65_6u_TyeB3Rmn5hzZYw&nd=1&dlsi=4f17dae5cf3f4306 - Agnete Fredriksen, Nykode | Being one of the top 50 women in 🇪🇺 Bio | E07: https://flot.bio/episode/agnete-fredriksen-top-women-bio/ - Flagship Pioneering website: https://www.flagshippioneering.com/ - Otello Stampacchia, Omega Funds 🇮🇹 | Competition, Boston & Pasta | E18: https://flot.bio/episode/otello-stampacchia-omega-funds/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/lovisa-afzelius-flagship-pioneering/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:08] Flagship Pioneering and their EU biotech initiatives [00:06:18] Being creative in many biotech spheres [00:08:37] Why invest 50m in first seed Series A every time? [00:11:42] The Flagship Pioneering business model: invest early [00:15:57] VC-created vs founder-led biotechs [00:17:46] Raising one of the largest biotech funds [00:19:19] Flagship Pioneering’s biggest returns [00:22:36] AI & biotech [00:26:31] What does success mean to Flagship Pioneering [00:29:20] How to help biotech spinoffs grow and advice for women to be biotech leaders [00:34:03] How to move from computational to translation sciences & bring drugs to market faster [00:37:14] What can the EU learn from the US to create biotechs [00:40:36] How do you bridge the gap between biotech company creation in the US vs EU [00:43:07] Lessons for an early-stage biotech career [00:47:18] How to attract the best biotech talent [00:48:38] Moving to Boston [00:52:13] Quickfire [00:55:41] Thanks for listening
We’re in Budapest with Szabolcs Nagy, the founder of Turbine, one of the leading companies for AI in biotech in the world. We talked about AI in biotech at large. We also cover the differences between opening a platform versus doing proprietary drug development and building the company from central Europe. __ This episode is sponsored by Turbine, which can improve your drug development. Learn more at https://shorturl.at/w3Im6 __ ⭐️ ABOUT THE SPEAKER I’ve known Szabolcs since 2017 when he joined Bayer’s accelerator in Berlin. I found him incredibly inspiring back then and still to this day. Szabi began his serial entrepreneurship with the creation of a cybersecurity startup. Once that was acquired, he launched himself into the biotech scene with the founding of Turbine in 2015. 🔗 LINKS MENTIONED - Accenture's Investment in Turbine Enhances AI-Powered Cell Simulations for Biopharma R&D: https://www.biopharmatrend.com/post/806-accentures-investment-in-turbine-enhances-ai-powered-cell-simulations-for-biopharma-rd/ - After a tough year, Exscientia folds into Recursion to create an AI superpower: https://www.fiercebiotech.com/biotech/after-tough-year-exscientia-folds-recursion-create-ai-super-power 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/szabolcs-nagy-ai/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. [🎙️](https://x.com/FlotBio) ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS
[00:00:00] Intro
[00:01:47] AI in Biotech
[00:09:03] Open platform vs proprietary drug development
[00:29:09] Pricing and value of AI technology in biotech
[00:38:19] Working with the average biotech
[00:42:42] History of Turbine and Szabolcs Nagy
[00:53:36] Data-driven drug development
[00:58:04] Quickfire
We’re online with Adrian Rawcliffe, the CEO of Adaptimmune, the TCR cell therapy company behind the first engineered cell therapy for solid tumors that was approved for a rare form of sarcoma. We talked about Tecelra's commercial rollout. We also talked about what's next in cell therapy, and Philly Cheesesteak vs Fish and Chips. — — — Thank you to today’s sponsor, Merck, who can support your antibody drug discovery. Learn more and claim a cool antibody pin here: https://bit.ly/3AhZFUA — — — ⭐️ ABOUT THE SPEAKER Adrian Rawcliffe has been in the biopharma industry for over 20 years and has worked in high positions for companies such as GSK. Adrian has been with Adaptimmune for almost 10 years, serving as CFO before becoming the CEO in 2019. I didn’t know him personally but have heard and seen great things about him. 🔗 LINKS MENTIONED - US FDA approves Adaptimmune's therapy for rare type of cancer: https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-adaptimmunes-gene-therapy-rare-cancer-2024-08-02/ - Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor: https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/271/adaptimmune-receives-u-s-fda-accelerated-approval-of - Galapagos selects Adaptimmune T-cell therapy for $665M biobucks collab: https://www.fiercebiotech.com/biotech/galapagos-selects-adaptimmune-t-cell-therapy-665m-biobucks-collab - FDA approves Iovance's Amtagvi as first T-cell therapy for a solid tumor: https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor - Fireside Chat with Adrian Rawcliffe, Chief Executive Officer of Adaptimmune: https://www.youtube.com/watch?app=desktop&v=AWIbHOJ1nUI&t=1121s - Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00319-2/abstract - Adaptimmune's CEO discusses last night's FDA accelerated approval of TECELRA, a TCR-based engineered cell therapy for synovial sarcoma: https://www.biotechtv.com/post/adaptimmune-august-2-2024 - Adrian’s LinkedIn profile: https://www.linkedin.com/in/adrawcliffe/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/adrian-rawcliffe-adaptimmune/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Introducing Adrian Rawcliffe [00:02:35] Commercial rollout of Tecelra, the first engineered cell therapy for solid tumors [00:07:35] The limits of TCR Cell Therapy [00:13:54] Market access in Europe [00:15:36] Peak sales projections [00:21:34] Next steps into 2025 [00:22:23] Rich History of Adaptimmune [00:28:47] GSK and transitioning to Biotech [00:35:54] BD & Partnering (or why not partner)[00:44:47] The Future of Cell Therapy: When will Allogeneic and In Vivo Therapies be on the Market? [00:48:43] Quick fire with Adrian Rawcliffe[00:50:20] Thanks for listening
We’re in Basel 🇨🇭 with the CEO of Nouscom, one of the top EU immuno-oncology biotechs in the cancer vaccine space, Marina Udier. We talked about cancer vaccines and Nouscom’s platform. We also discussed the importance of focus for success and her career. ⭐️ ABOUT THE SPEAKER Marina was recommended to me by one of her investors. She has an inspiring story, growing up in Croatia, going to the US, and making it all the way to be one of the 11% of female CEOs of biotechs in Europe in 2024. Now she is the CEO of Nouscom, but prior she was the Operating Principal at Versant Ventures, as well as holding top-level positions at Novartis Pharma, and McKinsey & Company. 🔗 LINKS MENTIONED - Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial - ****https://investors.modernatx.com/news/news-details/2022/Moderna-and-Merck-Announce-mRNA-4157V940-an-Investigational-Personalized-mRNA-Cancer-Vaccine-in-Combination-with-KEYTRUDAR-pembrolizumab-Met-Primary-Efficacy-Endpoint-in-Phase-2b-KEYNOTE-942-Trial/default.aspx?os=vb&ref=app - Agnete Fredriksen, Nykode | Being one of the top 50 women in 🇪🇺 bio | E07 - https://flot.bio/episode/agnete-fredriksen-top-women-bio/ - BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024 - https://investors.biontech.de/news-releases/news-release-details/biontech-present-clinical-data-updates-across-mrna-and - Nouscom Raises €67.5 Million ($72 Million) In Oversubscribed Series C Financing Round - https://nouscom.com/2023/11/14/nouscom-raises-e67-5-million-72-million-in-oversubscribed-series-c-financing-round-2-2/ 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/marina-udier-nouscom-cancer-vaccines/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. [🎙️](https://x.com/FlotBio) ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS - [00:00:00] Intro - [00:02:18] Cancer vaccines & Nouscom - [00:10:39] Bioinformatics algorithm - [00:15:16] Hype cycle in cancer vaccines - [00:26:04] $72M series C - [00:33:35] Managing a biotech board - [00:42:22] Personal story of Marina Udier - [00:48:17] Transition from Novartis - [00:54:00] Luck and timing in biotech - [00:56:10] Headwinds, Tailwinds - [00:58:13] Finding focus with a small team - [01:06:33] Gender diversity in biotech - [01:16:01] Quick fire - [01:18:37] Thanks for listening
We’re in Munich 🇩🇪 with the founder of one of the 15 most valuable European biotechs, Harpreet Singh. We talked about the field of PRAME receptors, TCR therapeutics and cell therapy at large. We also talked about the combination with mRNA therapeutics and his upbringing in a Sikh family in Germany.
🔗 LINKS MENTIONED Labiotech.eu | “Interview Harpreet Singh - Why Being in a New Field From the Start Can Pay Off in the Long Run”, Sep 2019: https://www.labiotech.eu/expert-advice/interview-singh-immatics/ Flot.bio | “Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity, and AI | E14”, Mar 2024: https://www.youtube.com/watch?v=8bmGke4sRvE Edwin Moses | How to Build Large Biotech Platforms (like Ablynx) | E13: https://youtu.be/oMBcFC3PqyM?si=xTcZF27F0UFjyQhb ApexOnco | Immatics’ PRAME gift keeps on giving: https://www.oncologypipeline.com/apexonco/immatics-prame-gift-keeps-giving
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/harpreet-singh-immatics/
💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio
🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.
⏰ TIMESTAMPS [00:00:00] Intro [00:02:00] PRAME & TCR space [00:12:43] Types of Cell Therapy [00:25:44] Commercialization [00:29:11] Valuations in Gene Therapy [00:33:17] Fundraising with Dievini and Struengmann [00:43:46] Sikh origin [00:48:31] Expanding to the US [00:53:59] PhD to CEO [00:59:21] Quickfire [01:03:01] Thanks for listening
